A Review of the Potential Mechanisms of Action of Baclofen in Alcohol Use Disorder

被引:31
|
作者
de Beaurepaire, Renaud [1 ]
机构
[1] Grp Hosp Paul Guiraud, Villejuif, France
来源
FRONTIERS IN PSYCHIATRY | 2018年 / 9卷
关键词
GABA receptor b; reward network; amygdala; Pavlovian associations; substitution; (morphine; methadone; buprenorphin); HIGH-DOSE BACLOFEN; VENTRAL TEGMENTAL AREA; GABA-B RECEPTOR; POSITIVE ALLOSTERIC MODULATOR; MESOLIMBIC DOPAMINE SYSTEM; TERM ABSTINENT ALCOHOLICS; RESTING-STATE SYNCHRONY; CENTRAL-NERVOUS-SYSTEM; PREFERRING SP RATS; BINGE-LIKE ETHANOL;
D O I
10.3389/fpsyt.2018.00506
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Baclofen, a GABA-B receptor agonist, is a promising treatment for alcohol use disorder (AUD). Its mechanism of action in this condition is unknown. GABA-B receptors interact with many biological systems potentially involved in AUD, including transduction pathways and neurotransmitter systems. Preclinical studies have shown that GABA-B receptors are involved in memory storage and retrieval, reward, motivation, mood and anxiety; neuroimaging studies in humans show that baclofen produces region-specific alterations in cerebral activity; GABA-B receptor activation may have neuroprotective effects; baclofen also has anti-inflammatory properties that may be of interest in the context of addiction. However, none of these biological effects fully explain the mechanism of action of baclofen in AUD. Data from clinical studies have provided a certain number of elements which may be useful for the comprehension of its mechanism of action: baclofen typically induces a state of indifference toward alcohol; the effective dose of baclofen in AUD is extremely variable from one patient to another; higher treatment doses correlate with the severity of the addiction; many of the side effects of baclofen resemble those of alcohol, raising the possibility that baclofen acts as a substitution drug; usually, however, there is no tolerance to the effects of baclofen during long-term AUD treatment. In the present article, the biological effects of baclofen are reviewed in the light of its clinical effects in AUD, assuming that, in many instances, clinical effects can be reliable indicators of underlying biological processes. In conclusion, it is proposed that baclofen may suppress the Pavlovian association between cues and rewards through an action in a critical part of the dopaminergic network (the amygdala), thereby normalizing the functional connectivity in the reward network. It is also proposed that this action of baclofen is made possible by the fact that baclofen and alcohol act on similar brain systems in certain regions of the brain.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Genetics of alcohol use disorder: a review
    Deak, Joseph D.
    Miller, Alex P.
    Gizer, Ian R.
    CURRENT OPINION IN PSYCHOLOGY, 2019, 27 : 56 - 61
  • [32] The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
    Tap, Stephan C.
    ADDICTION BIOLOGY, 2024, 29 (04)
  • [33] Baclofen for Alcohol Use Disorder: A systematic review and meta-analysis of the randomized clinical trials focusing on safety outcomes
    Lefebvre, L.
    Sanaei, S.
    Kassai, B.
    Rolland, B.
    Auffret, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 129 - 130
  • [34] Alcohol Use Disorder in the Age of Technology: A Review of Wearable Biosensors in Alcohol Use Disorder Treatment
    Davis-Martin, Rachel E.
    Alessi, Sheila M.
    Boudreaux, Edwin D.
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [35] Alcohol metabolism in alcohol use disorder: a potential therapeutic target
    Lehner, Taylor
    Gao, Bin
    Mackowiak, Bryan
    ALCOHOL AND ALCOHOLISM, 2024, 59 (01):
  • [36] Therapeutic potential of ketamine for alcohol use disorder
    Worrell, Stephen D.
    Gould, Thomas J.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2021, 126 : 573 - 589
  • [37] BACLOFEN FOR TREATMENT OF ALCOHOL USE DISORDER: SECONDARY ANALYSES AND IMPLICATIONS OF THE AUSTRALIAN BACALD TRIAL
    Morley, Kirsten
    Luquin, Natasha
    Lagopoulos, Jim
    Logge, Warren
    Baillie, Andrew
    Haber, Paul S.
    DRUG AND ALCOHOL REVIEW, 2019, 38 : S75 - S75
  • [38] How to Manage Self-Poisoning With Baclofen in Alcohol Use Disorder? Current Updates
    Franchitto, Nicolas
    Rolland, Benjamin
    Pelissier, Fanny
    Simon, Nicolas
    FRONTIERS IN PSYCHIATRY, 2018, 9
  • [39] Acamprosate for the treatment of alcohol use disorder may be safer than baclofen in patients with cirrhosis
    Tyson, Luke D.
    Cheng, Alexandra
    Kelleher, Charles
    Strathie, Kirstin
    Lovendoski, James
    Habtemariam, Zebib
    Lewis, Heather
    JOURNAL OF HEPATOLOGY, 2021, 75 : S314 - S314
  • [40] High-dose baclofen for alcohol use disorder: A very troubled French exception?
    Braillon, Alain
    Naudet, Florian
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2025, 209 (02): : 326 - 327